Month: August 2021

The biotechnology company working to eliminate the organ transplant waitlist outlines expansion of its clinical work, supported by IPO funds and Series C round, led by Baxter, CareDx, and DaVita EDEN PRAIRIE, Minn., Aug. 11, 2021 (GLOBE NEWSWIRE) — Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save patients’ lives and improve quality of life around the world, announced strategic investors involved in its Series C financing, which was followed by its June 24th IPO. The Company outlined clinical initiatives and operational expansions as part of its investment plan for 2021 and 2022 focused on their liver and kidney programs. The additional funding will help accelerate Miromatrix’ progress towards initiating a clinical...

Las Vegas, Aug. 11, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — GZ6G Technologies (OTCMarkets: GZIC), the complete enterprise smart solutions provider for large venues and cities, announced that on August 6, 2021 it finalized its OTCQB uplisting application and hopes to have the OTC finalize the uplist process by Friday, August 20, 2021. In conjunction with the completion of the uplist application, GZ6G Technologies has appointed two new board members; Mr. Scott Hale and Mr. William Procanik. Both bring a wealth of experience in the business sector and will be a welcome addition to the future plans of the Company and its growth. “We’re one step closer to becoming a fully reporting Securities and Exchange Commission (“SEC”) issuer. We continue to meet our milestones and have chosen board members who are comprised of a dedicated...

Picture 1In the third episode of “In My City: Denver”, a series produced by HipHopDX (a channel owned by Warner Music Group), Peak was featured as an iconic contributor to Denver’s music scene, with patronage from high-profile recording artists. This episode can be viewed by clicking the thumbnail above or by clicking here.DENVER and VANCOUVER, British Columbia, Aug. 11, 2021 (GLOBE NEWSWIRE) — SPOTLITE360 TECHNOLOGIES, INC. (“Spotlite360” or the “Company”) (CSE: LITE) (OTC: SPLTF) (Frankfurt: 87A) is pleased to announce that it has entered into a master terms agreement (the “Agreement”) with Peak Dispensary (“Peak”), a cannabis dispensary operator with locations in Denver and Sedgwick, Colorado, to develop scopes of work for the integration of the Company’s suite of technologies (the “Spotlite360 Technologies”)...

Strong growth in net cash provided by operating activities (GAAP) and Adjusted Cash Flow(2) Announced transactions of up to $2.8 billion in 2021, including $2.1 billion* in upfront payments Increased 2021 guidance: Adjusted Cash Receipts(1) expected to be $2,080 to $2,120 millionNEW YORK, Aug. 11, 2021 (GLOBE NEWSWIRE) — Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the second quarter of 2021 and raised full-year 2021 guidance for Adjusted Cash Receipts(1) (a non-GAAP financial measure). “Since our initial public offering a little more than a year ago, we have announced acquisitions totaling $4.7 billion, which is a testament to the strength of our business model and leadership position in the rapidly growing biopharma royalty funding market,” said Pablo Legorreta, Royalty Pharma founder and Chief Executive...

Company delivered net sales of $3.1 million on 8.6 million pounds of tomatoes sold,concluding the abbreviated 2020 planting season Secured $91 million in new, non-dilutive financing from leading sustainability investor Equilibrium Capital and $75 million from Rabo AgriFinance with four farms under construction Company reaffirms long-term 2025 outlook reflecting expected benefits of proprietary technology, plans to launch value-added product line; reduces 2021 outlook based on operational ramp-up challenges and dedicating more production space to strategic investments AppHarvest President David Lee assumes operational responsibility with key seasoned executive recruits supporting AppHarvest 2.0 initiative MOREHEAD, Ky., Aug. 11, 2021 (GLOBE NEWSWIRE) — AppHarvest, Inc. (NASDAQ: APPH, APPHW), a leading AgTech company, public benefit...

EDISON, N.J., Aug. 11, 2021 (GLOBE NEWSWIRE) — Eos Energy Enterprises, Inc. (NASDAQ: EOSE) (“Eos”), a leading provider of safe, scalable, efficient, and sustainable zinc-based energy storage systems, today announced financial results for the second quarter ended June 30, 2021 and updated guidance for full year 2021. Recent Business HighlightsBooked orders of $79.2 million year-to-date resulting in backlog of $95.6 million, as of August 11, 2021; current backlog delivers 100% coverage on 2021 $50 million revenue target $2 million in product shipped, as of August 11, 2021 Successfully completed UL certification on August 10, 2021 On July 7, 2021, Eos announced $100 million investment from Koch Strategic Platforms, a subsidiary of Koch Investments Group, to support the Company’s strategic growth initiativesEos Chief...

Completed a successful pre-IND meeting with the FDA for VRDN-001, a differentiated monoclonal antibody targeting IGF-1R for the treatment of Thyroid Eye DiseaseOn track to submit an IND filing with the FDA for VRDN-001 in the fourth quarter of 2021 and for key proof of concept clinical data in Thyroid Eye Disease patients in the second quarter of 2022 First VRDN-001 clinical trial data has potential to show rapid and substantial reduction in proptosis, the defining symptom of Thyroid Eye Disease Multiple abstracts accepted for upcoming presentation at the American Thyroid Association (ATA) Annual Meeting, highlighting preclinical data for Viridian’s differentiated IGF-1R antibodies Strengthened management team with appointments of Kristian Humer as Chief Financial Officer and Chief Business Officer and Deepa Rajagopalan, M.D. as SVP...

SAN FRANCISCO, Aug. 11, 2021 (GLOBE NEWSWIRE) — FibroGen, Inc. (NASDAQ: FGEN) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter regarding the New Drug Application (NDA) for roxadustat for the treatment of anemia of chronic kidney disease (CKD). The letter indicates the FDA will not approve the roxadustat NDA in its present form and has requested additional clinical study of roxadustat be conducted, prior to resubmission.   “We are deeply disappointed with this result, and this is an unfortunate day for patients suffering from anemia of CKD in the United States,” said Enrique Conterno, Chief Executive Officer, FibroGen. “Roxadustat is changing the lives of patients around the world, and we and our partner AstraZeneca will discuss next steps in the U.S.” Roxadustat is approved...

•  Recruitment Progressing as Planned with Over 300 Patients Enrolled into Phase 3 SHIELD I Trial of D-PLEX100 in Abdominal Surgery •  FDA Agreed that a Single Pivotal Phase 3 Study is Sufficient for Potential Approval of D-PLEX100 for the Prevention of Surgical Site Infections in Colorectal Surgery •  Brain Tumors Selected as the Initial Indication for Company’s OncoPLEX Intra-tumoral Cancer Therapy Program •  Conference Call Scheduled for Today at 8:30 AM ET PETACH TIKVA, Israel, Aug. 11, 2021 (GLOBE NEWSWIRE) — PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharma company aiming to improve surgical outcomes through locally administered, controlled, extended-release therapeutics, today provided a corporate update and reported financial results for the three and six months ended June 30, 2021. Recent Corporate Highlights:Recruitment...

Highlights:Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021Partnership being developed with leading UK institutions to accelerate psychedelic research and develop new models of mental health care in the UKGuy Goodwin appointed Chief Medical Officer and Danielle Schlosser appointed Senior Vice-President, Clinical Innovation“Everyone has a story: talking about mental health” podcast launched to eliminate stigma and open up dialogueConference call today at 1:00pm UK (8:00am ET)LONDON, Aug. 11, 2021 (GLOBE NEWSWIRE) — COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the second...